



D8.9

Dissemination of ELISA and antibodies (flyer)

Project title: Screening of inFlammation to enable personalized Medicine: *SciFiMed*

Grant Agreement No.: 899163

Call identifier: H2020-FETOPEN-2018-2020

Coordinator: Philipps Universität Marburg – UMR

Project start date: 1st of January 2021

Duration: 48 months

Deliverable type:	D38
Task and Work package contributing to the deliverable:	WP8
Due date:	30 th of September 2023
Actual submission date:	11 th of October 2023

Responsible lead organisation:	Hbt
Lead Author:	Loek Willems, Hbt
Dissemination level:	Public
Revision Date:	-
Document Reference:	D8_9_Flyer



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 899163.

Revision/ Review No.	Date [month/day/year]	Work performed	Contributor
1	August/15/2023	Design of flyer	HBT
2	August/31/2023 - October/6/2023	Introduction to international scientific meetings	HBT
3	October/11/2023	Format revision	UMR (Pauly)



Disclaimer

This document reflects only the author's view. Responsibility for the information and views expressed therein lies entirely with the authors. The European Commission is not responsible for any use that may be made of the information it contains.



Summary

Project flyer designed to include exploitable reagents from SciFiMed project. First commercially available antibodies to FHR-2, FHR-3, FHR-4 and FHR-5 are announced as well as prototype ELISA kits for FHR-2, FHR-3, FHR-4 and FHR-5.

Also dissemination of posters at the International Complement Workshop (Newcastle, UK), by SciFiMed members are included in the flyer.

The flyer was first introduced at International Complement Workshop (Newcastle, UK), August 31st – September 5th 2023 and is used for communication activities at any relevant events thereafter.

Contents

1. Activities performed	6
1.1. Realisation of D8.9 and dissemination activities	6
2. Initial market feedback	9

1. Activities performed

As part of the dissemination and exploitation plan the introduction of exploitable products as well as project updates was envisioned in a dissemination activity.

A flyer for dissemination ELISA/ Antibodies/ Antigens was originally planned for 31st of December 2022 and rescheduled to be executed before 30th of September 2023. Main reasons are better timing with the first release of exploitable reagents as well as maximum exposure at the most relevant scientific meetings involving work on complement and Factor H. This includes the biggest international scientific meeting on complement held every 2 years.

A project flyer has been designed to include current exploitable reagents from SciFiMed project. This includes the first commercially available antibodies to FHR-2, FHR-3, FHR-4 and FHR-5 as a result of a joint effort between Hbt/SAN.

The flyer also includes prototype ELISA kits for FHR-2, FHR-3, FHR-4 and FHR-5 as jointly developed by Hbt/SAN.

The awareness on prototype ELISA kits is used to encourage scientists to engage outside the project.

The flyer also includes dissemination of posters of most recent work of various work packages.

1.1. Realisation of D8.9 and dissemination activities

A concept version of the flyer as well as content has been generated by Hbt on the basis of the original SciFiMed flyer designed by UMR with input by all SciFiMed partners. The design of the definite flyer has been completed on 15th of August 2023.

OUR AMBITION

Our EU consortium has an ambition to unravel the mysteries of the FH-protein family's contributions to diseases¹. These efforts are leading to new technology and improved methods to investigate FH-related proteins. Tools developed and validated within the project will become available for research use only (RUO).

¹ Banerjee, Pratiti, Bert Veuskens, Elena Golcochea de Jorge, Mihály Józsi, Antje J. Baemmer, Mark-Steven Steiner, Richard B. Pouw, et al. 2022. "Evaluating the Clinical Utility of Measuring Levels of Factor H and the Related Proteins." *Molecular Immunology* 151 (November): 166-82.

PRE-RELEASE

Assays under development:

- Human FHR-2 ELISA
- Human FHR-3 ELISA
- Human FHR-4 ELISA
- Human FHR-5 ELISA

For a limited period Hycult Biotech is able to offer early access to prototype ELISA kits. Inquire for terms and conditions to obtain these assays developed within SciFiMed project.

SciFiMed UPDATES

Presented at ICW 2023:

- Factor H-related dimer equilibrium and kinetics revealed through novel specific ELISAs *Veuskens BMC, Brouwer MC, Gelssier J, van Leeuwen K, Kullpers TW, Pouw RB; on behalf of the SciFiMed Consortium*
- Factor H-related proteins bind to extracellular matrix components and affect complement activation. *Papp A, Bencze D, Uzonyi B, Márquez-Tirado B, Golcochea de Jorge E, Józsi M; on behalf of the SciFiMed Consortium*
- Interaction of factor H and factor H-related proteins with S and N proteins of SARS-CoV-2 *Barbal VH, Papp A, Bencze D, Uzonyi B, Józsi M; on behalf of the SciFiMed Consortium*
- A novel CFHR3-1 hybrid protein provides insight into the pathogenic mechanisms leading to C3 glomerulopathy *Márquez-Tirado B, Martín Merinero HM, Lucientes-Contiente L, Jiménez Villegas L, Rodríguez de Córdoba S, Golcochea de Jorge, E. Complutense University of Madrid and CSIC Madrid*

FIRST TOOLS

Mouse monoclonal antibodies to:

- Human FHR-2
- Human FHR-3
- Human FHR-4
- Human FHR-5

These antibodies are developed by Sanquin Blood Supply Foundation, available by various SciFiMed partners and commercially available via Hycult Biotech.

FIND OUT MORE

www.scifimed.eu [/scifimed](https://www.youtube.com/channel/UCscifimed)

PARTICIPATING PARTNERS:

SCREENING OF INFLAMMATION TO ENABLE PERSONALIZED MEDICINE

SciFiMed has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 899163

Frontpage flyer including reagents and SciFiMed updates



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 899163.

WHY SciFiMed

The Factor H (FH)-protein family is a group of seven proteins that belong to a specific part of the immune system, called the complement system. Problems with the FH-protein family have been linked to infections, but also to kidney and eye diseases, affecting millions of people.

The exact function of the FH-protein family is unknown and therefore, many questions remain unanswered, such as how they contribute to diseases.



WHAT WE DO

Our EU consortium will unravel the mysteries of the FH-protein family's contributions to diseases.

Using transdisciplinary fundamental science-to-technology transfer we will develop a new smart device that will allow for analysing the levels and activity of FH-protein family members in patients' samples at the bedside.

This high-impact project will propel immunological research in Europe, enable product development of bioanalytical companies, modernize the EU diagnostic market and provide new perspectives for patient treatment paving the way for drug development.


For updates on SciFiMed project see our website: <https://www.scifimed.eu/> or follow our socials. Any requests for specific project information or technologies in progress, fill out this form: <https://www.scifimed.eu/contact>.

WHO WE ARE

We are eight partners from four countries and eight universities and companies.

SciFiMed supports young scientists, female coordinator and a balanced gender ratio.

UNMET NEEDS



Antje Baeumner
University Regensburg
Germany

Mihály Józsi
Eötvös Loránd University
Hungary

Richard B. Pouw
Sanquin
The Netherlands

Erik J.M. Toonen
Hycult Biotechnology
The Netherlands

Elena Goicoechea de Jorge
University Complutense Madrid
Spain

Felix Poppelaars
University Medical Centre Groningen
The Netherlands

Günter Müller
Microcoat Biotechnologie
Germany

Diana Pauly (Coordinator)
University of Marburg
Germany



Inside of the flyer including background on SciFiMed and contact information

The flyer was first introduced at **International Complement Workshop (Newcastle, UK), August 31st – September 5th 2023** at the booth of Hbt. Thereby the public introduction of D8.9 has been released early September.

Dissemination activities with this flyer are also performed at **7th Complement-based Drug Development Summit 2023 (Boston, USA), September 12th-13th, 2023**, and **Dutch Complement Symposium (Nunspeet, The Netherlands), October 6th 2023**.



Hycult Biotech @HycultBiotech · 1 sep.

Catch up with our team at [#ICW2023](#). We present interesting new tools for complement research, such as new pathway activation assays and first FHR antibodies from [@SciFiMed](#) project.



Photo of booth at ICW meeting in Newcastle, including the flyer, and Twitter/X feed for wider public



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 899163.



Hycult Biotech @HycultBiotech · 6 okt.

...

Richard Pouw from Sanquin talking about Factor H, FHR and @SciFiMed work at Dutch Complement Symposium 2023. New FHR antibodies and ELISA also presented at Hycult table



5



6



185



Presentation at Dutch Complement Symposium as well as flyer at booth. Twitter/X feed for wider public



2. Initial market feedback

To date, 9th of October 2023, the three consecutive meetings have gained a first interest in any of the upcoming SciFiMed reagents. At least six academic partners outside SciFiMed and three pharmaceutical companies have expressed their early interest in the antibodies and/or ELISA kits. Two to three partners that might be interested in using the prototype ELISA kits with their patient cohorts. This to be further examined via the WP2 and WP6 partners, in order to align this with their activities in order not to jeopardize pending studies within the consortium.